Author

T. Herold

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

I. Jeremias· 2 shared M. Carlet· 2 shared W.-H. Liu· 2 shared A. Arner· 1 shared A. Feber· 1 shared A. M. N. Batcha· 1 shared A. Unnikrishnan· 1 shared A.-K. Wirth· 1 shared

Activity by Year

2019-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

I. Jeremias

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets

M. Carlet, K. Voelse, J. Vergalli, M. Becker, T. Herold, A. Arner, W.-H. Liu, V. Dill, B. Fehse, C. D. Baldus, L. Bastian, L. Lenk, D. M. Schewe, J. W. Bagnoli, P. J. Jost, , I. Jeremias

The paper develops an in vivo inducible RNAi system in patient-derived xenograft models to identify therapeutic targets in acute leukemias.

bioRxiv · May 2, 2020Cancer Biology

Inducible transgene expression in PDX models in vivo identifies KLF4 as therapeutic target for B-ALL

W.-H. Liu, P. Mrozek-Gorska, T. Herold, L. Schwarzkopf, D. Pich, K. Völse, A.-K. Wirth, M. C. Melo-Narvaez, M. Carlet, W. Hammerschmidt, I. Jeremias

The paper uses PDX models to show KLF4 re-expression reduces B-ALL leukemia load and sensitizes tumors to chemotherapy, suggesting Azacitidine could regulate KLF4 as a therapeutic option.

bioRxiv · Mar 6, 2020Cancer Biology

RNA splicing alterations induce a cellular stress response associated with poor prognosis in AML

G. Anande, N. P. Deshpande, S. Mareschal, A. M. N. Batcha, H. R. Hampton, T. Herold, S. Lehmann, M. R. Wilkins, J. W. H. Wong, A. Unnikrishnan, J. E. Pimanda

The paper identifies RNA splicing alterations in AML patients without splicing factor mutations, linking them to stress response and poor prognosis through machine learning.

bioRxiv · Jan 10, 2020Cancer Biology

SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine

T. Rothenburger, K.-M. McLaughlin, T. Herold, C. Schneider, T. Oellerich, F. Rothweiler, A. Feber, T. R. Fenton, M. N. Wass, O. Keppler, M. N. Michaelis, J. Cinatl

This study identifies SAMHD1 as a key regulator of nelarabine response in acute lymphoblastic leukaemias, showing lineage-specific differences in SAMHD1 expression and methylation.

bioRxiv · Dec 3, 2019Pharmacology & Toxicology